v3.25.1
Description of Operations and Summary of Significant Accounting Policies (Details)
$ in Billions
3 Months Ended 12 Months Ended
Mar. 31, 2025
USD ($)
Customer
Mar. 31, 2024
Customer
Dec. 31, 2024
Description of Operations and Summary of Significant Accounting Policies      
Number of major customers | Customer 3 3  
Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer One      
Description of Operations and Summary of Significant Accounting Policies      
Concentration Risk, Percentage 29.00% 36.00%  
Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer Two      
Description of Operations and Summary of Significant Accounting Policies      
Concentration Risk, Percentage 27.00% 26.00%  
Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer Three      
Description of Operations and Summary of Significant Accounting Policies      
Concentration Risk, Percentage 27.00% 24.00%  
Customer Concentration Risk | Receivables from Net Product Sales | La Jolla [Member] | Customer One      
Description of Operations and Summary of Significant Accounting Policies      
Concentration Risk, Percentage 33.00%   31.00%
Customer Concentration Risk | Receivables from Net Product Sales | La Jolla [Member] | Customer Two      
Description of Operations and Summary of Significant Accounting Policies      
Concentration Risk, Percentage 18.00%   24.00%
Customer Concentration Risk | Receivables from Net Product Sales | La Jolla [Member] | Customer Three      
Description of Operations and Summary of Significant Accounting Policies      
Concentration Risk, Percentage 20.00%   24.00%
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | RELVAR/BREO      
Description of Operations and Summary of Significant Accounting Policies      
Royalty rate for first level of annual global net sales (as a percent) 15.00%    
Annual global sales level used to determine royalty rate | $ $ 3.0    
Royalty rate for sales above first level of annual global net sales (as a percent) 5.00%    
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Minimum      
Description of Operations and Summary of Significant Accounting Policies      
Royalty rate for combination products (as a percent) 6.50%    
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Maximum      
Description of Operations and Summary of Significant Accounting Policies      
Royalty rate for combination products (as a percent) 10.00%